The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women

ObjectivesMost breast cancer cases in Ghana occur premenopausal and perimenopausal (PPM) women. This study evaluated the cost-effectiveness of tamoxifen compared with no for adjuvant treatment hormone receptor–positive (HR+) early (EBC) among PPM Ghanaian women.MethodsA Markov model was constructed to synthesize data on effectiveness, costs, health benefits tamoxifen. Effectiveness utility were sourced from a literature review. Resource use healthcare costs estimated sources. The evaluation conducted 2017 perspective system over 15-year time horizon. financial impact funding Ghana’s National Health Insurance Scheme (NHIS) also estimated.ResultsAdjuvant women HR+ EBC more effective costly than no-tamoxifen therapy. incremental benefit be 1.38 quality-adjusted life-years gained cedis (GHC) 2338 ($520), respectively. ratio GHC 1694 ($376). sensitive cost values. represents less 0.01% 96 960 ($21 547) current NHIS total claims expenditure.ConclusionsTamoxifen provides additional is cost-effective These results support public under provide policy makers vital information future budgetary planning.